Drugs for rare diseases looming health hazard

The problem is that such niche drugs are often exorbitantly expensive, says Rieder, chair of the Canadian Pediatric Society’s drug therapy committee: “The trouble is you’re not selling it to millions of people, you’re selling it to tens of thousands of people, or in the case of ivacaftor, you’re selling it to maybe thousands of people … globally.”